Shire bid marks Takeda’s latest – and biggest – push for global status

TOKYO (Reuters) – Takeda Pharmaceutical Co Ltd’s $64 billion bid for London-listed rare disease specialist Shire Plc bolsters its credentials as Japan’s most outward facing drugs firm, a mould-breaking image that has been more than a decade in the making.

Powered by WPeMatico

Scroll to top